Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection

Scavizzi, M; Alonso, Jean-Michel; Philippon, A.; Jupeau-Vessieres, A. M.; Guiyoule, Annie

doi:10.1128/aac.31.4.523

Cited by 23 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the first series of in vivo experiments, we used the same model as described previously with Y. enterocolitica (31). In fact, these experiments were performed as a screening of the in vivo antibiotic activity.…”

Section: Methodsmentioning

confidence: 99%

“…Newer P-lactam antibiotics were suggested as alternatives in severe Yersinia-infections (20,21,32,37). However, an animal model showed that the treatment of mice infected by Y. enterocolitica failed with the newer P-lactams despite in vitro susceptibility of the strain (31). Therefore, we checked the in vivo efficacy of old and newer P-lactams and other in vitro active antibiotics (e.g., fluoroquinolones) against Y. pseudotuberculosis (a P-lactamase nonproducer), in a reproducible mouse model mimicking natural systemic infection (3,35).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection

Lemaitre

Mazigh

Scavizzi

1991

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection

Lemaitre

Mazigh

Scavizzi

1991

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

“…In animal models, the expanded-spectrum cephalosporins and imipenem have failed in the treatment of other yersinioses despite having good in vitro activity (4,9). In contrast, ceftriaxone was as effective as ofloxacin or streptomycin in a murine model of Y. pestis infection (1).…”

mentioning

confidence: 99%

In vitro antimicrobial susceptibilities of strains of Yersinia pestis

Smith

Vinh

Nguyen

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…the two other pathogenic yersiniae (19,26,28); we also tested another aminoglycoside (gentamicin), an aminopenicillin (amoxicillin), and another cycline (doxycycline). In the study described here, we used a reproducible systemic Y pestis infection in mice caused by a virulent isolate from a human.…”

mentioning

confidence: 99%

Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection

Bonacorsi

Scavizzi

Guiyoule

et al. 1994

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Amoxicillin, cefotaxime, ceftriaxone, gentamicin, doxycycline, and ofloxacin were active in vitro, like the reference drug streptomycin, against the virulent strain Yersinia pestis 6/69M. The comparative efficacies of these drugs in vivo were evaluated in a standardized and reproducible mouse model of systemic infection. Each antibiotic was injected intravenously once, at 24 h postinfection, and then repeatedly during 48 h. In vivo results were measured by counting the viable bacteria recovered from the whole spleens of mice sacrificed at selected times. All the drugs were manifestly successful; ceftriaxone, ofloxacine, and the reference drug were the most effective. Therefore, gentamicin and doxycycline could be used, depending on the clinical forms of the Y. pestis infection. Further investigations on beta-lactams, especially those used in the present study, could be carried out to confirm or not confirm their activities against Y. pestis. Ofloxacin appeared to be as active and to perform as rapidly as streptomycin in the treatment of murine Y. pestis infection, which is in agreement with the previous successes obtained with the use of fluoroquinolones in the treatment of murine infections caused by other pathogenic yersiniae.Three pathogenic species are included in the genus Yersinia. Y enterocolitica and Y pseudotuberculosis essentially cause gastroenteritis and occasionally septicemia. Y pestis, which was discovered in 1894 by Alexandre Yersin, is the agent of plague.Despite the efforts of public health workers to control plague, this infection still has a widespread distribution in the world (7,20,22,25,35). During the last decade (1980 to 1989), 21 countries notified the World Health Organization of almost 10,000 cases of plague, and the global fatality rate was 11.5%, with peaks in some countries exceeding 35% (35). If, at the moment, the worldwide incidence seems to be stable, a few countries regularly report an increasing number of cases. In the four past decades (the 1950s, 1960s, 1970s, and 1980s), the United States has recorded 10, 28, 105, and 179 cases of plague, respectively (6, 35). Septicemic plague, which is difficult to recognize, may represent 20 to 25% of the cases of plague in the United States (17, 34). Secondary localizations, for example, pulmonary or meningeal, may complicate 6% of cases of bubonic or septicemic plague (3, 5) and up to now have been characterized by a high death rate, in some reports rising to 33% (2, 17).Forty years ago, Meyer (23) considered streptomycin, chloramphenicol, and tetracyclines to be reference drugs for the treatment of plague, and they are still recommended for that use today (3). This limited antibiotic choice can be a serious handicap because of (i) localization of the disease (e.g., meningitis), (ii) underlying disease, or (iii) antibiotic side effects.In the face of this dilemma, it seemed to us that it would be useful to evaluate the in vivo comparative efficacies of newer antibiotics like fluoroquinolones and extended-spectrum cephalosporins agains...

show abstract

Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection

Cited by 23 publications

References 31 publications

Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection

Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection

In vitro antimicrobial susceptibilities of strains of Yersinia pestis

Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection

Contact Info

Product

Resources

About